Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
sequential R-CHOP · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | All patients will receive 4 courses of rituximab on days 1, 8, 15 and 22. Patients achieving a CR after the first 4 applications of single agent rituximab (evaluated between day 40 to 50) will go on with 4 further courses of single agent rituximab on days 50, 72, 94 and 116. |
| B | EXPERIMENTAL | All patients will receive 4 courses of rituximab on days 1, 8, 15 and 22. Patients who do not achieve a CR after the first 4 applications of single agent rituximab (evaluated between day 40 to 50) will go on with 4 courses of R-CHOP on days 50, 72, 94 and 116. |
| Name | Type | Description |
|---|---|---|
| rituximab monotherapy | DRUG | 375 mg/m2, IV on days 1, 8, 15, 22, 50, 72, 94 and 116. In case of disease progression during the first 4 administration of rituximab antibody or the 4 weeks interval between course 4 and 5 the patients directly enter R-CHOP chemotherapy (Arm B). |
| sequential R-CHOP | DRUG | 375 mg/m2 rituximab, IV on days 1, 8, 15, 22, 50, 72, 94 and 116. Cyclophosphamid 750 mg/m2, adriamycine 50 mg/m2 and vincristine 1.4mg/m2, IV and prednisone 50mg/m2, PO every 3 weeks at days 50, 72, 94 and 116. In case of disease progression during the first 4 administration of rituximab antibody or the 4 weeks interval between antibody and R-CHOP administration the patients directly enter R-CHOP chemotherapy. |
Inclusion Criteria: * PTLD with or without EBV association, confirmed after biopsy or resection of tumor * Measurable disease of \> 2 cm in diameter and/or bone marrow involvement * Patients having undergone heart, lung, liver, kidney, pancreas, small intestine transplantation or other or a combina...
Sequential R-CHOP is used for post-transplant lymphoproliferative disorder (PTLD), a condition that can occur after organ transplantation. It is a treatment regimen being studied in patients with CD20-positive PTLD.
Sequential R-CHOP is being developed by Pulmonx Corporation, which trades under the ticker LUNG on the stock market. The company is conducting clinical research on this treatment for PTLD.
Sequential R-CHOP is in Phase 2 clinical development. It is an investigational treatment for PTLD and has not yet been approved by regulatory authorities. The Phase 2 trial has been completed.
Sequential R-CHOP is being studied in a completed Phase 2 trial with the identifier NCT00590447, titled 'Risk Stratified Sequential Treatment for CD20-positive PTLD.' The trial enrolled 152 participants across multiple countries including Australia, Belgium, France, Germany, Italy, Poland, and Sweden.
Sequential R-CHOP is a specific regimen that involves giving R-CHOP in a sequential manner, as opposed to standard R-CHOP. It is being studied for PTLD, and the trial focuses on risk-stratified treatment for CD20-positive PTLD.